arrow
K

Kristen Spencer

university of colorado anschutz medical campus
H指数:17
被引数:2,221

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer

Lentz, R.W.; Lang, J.; Pitts, T.M.; Blatchford, P.; Hu, J.; Jordan, K.R.; Van Bokhoven, A.; Bagby, S.M.; Dominguez, A.T.A.; Binns, C.A.; 等. 一种新型CD47阻断联合疗法在难治性微卫星稳定型转移性结直肠癌中的II期临床试验及临床前评估. Cancer Res. Commun. 2025, 5, 2039–2052. [Google Scholar] [CrossRef] [PubMed]

2025-11-011
PRE
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial

奥拉帕尼治疗难治性异柠檬酸脱氢酶1 (IDH1) 和IDH2-mutant胆管癌: 来自美国国家癌症研究所10129期2试验的安全性和抗肿瘤活性

CANCER
IF5.1
2025-02-070
PRE
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E

Pembrolizumab联合Binimetinib联合化疗或不联合化疗治疗MSS/pMMR转移性结直肠癌: 来自651主题的队列A、C和E的结果

2024-06-010
PRE
Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D

Pembrolizumab联合mFOLFOX7或FOLFIRI治疗微卫星稳定/错配修复熟练的转移性结直肠癌: 主题演讲-651队列B和D

2024-06-014
PRE
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
2023-12-224
OA
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma
2023-04-119
OAAI
A PHASE 1 STUDY EXPLORING THE SAFETY AND TOLERABILITY OF THE SMALL MOLECULE PD-L1 INHIBITOR, INCB086550, IN PATIENTS WITH SELECT ADVANCED TUMORS
2022-11-070
OA
Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study

通过在线肿瘤委员会使社区肿瘤学家可以访问国家癌症研究所指定的综合癌症中心知识: 纵向观察研究

2022-05-191
OA
Pembrolizumab for previouslytreated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study
2022-05-0136
OAAI
A PHASE 1B MULTI-TUMOR COHORT STUDY OF CABOZANTINIB PLUS ATEZOLIZUMAB IN ADVANCED SOLID TUMORS: RESULTS OF THE TRIPLE-NEGATIVE BREAST CANCER, OVARIAN CANCER, AND ENDOMETRIAL CANCER COHORTS
2021-11-101
OA
A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study
2020-08-159
PRE